Mink parvovirus attenuated vaccine strain and application of mink parvovirus attenuated vaccine strain in preparation of mink parvovirus attenuated vaccine
A technology of mink parvovirus and attenuated vaccine, applied in antiviral agents, viruses/phages, microorganism-based methods, etc., can solve problems such as hidden dangers of vaccine use in the next step, incomplete inactivation, and impact on the quality of mink skins.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0019] Example 1 Passage weakening of mink parvovirus MEVB
[0020] 1. Passage weakening of mink parvovirus MEVB
[0021] (1) The mink parvovirus vaccine strain MEVB was inoculated on cat kidney cells CRFK by synchronous inoculation for virus amplification and culture, and the cell lesion was observed every day. When the cell lesion reached about 80%, it could be frozen and thawed repeatedly. The virus was harvested using the method described above and labeled MEVB-F1 (passage 1).
[0022] (2) The first-generation virus MEVB-F1 was inoculated and harvested according to the method described above, and the virus was labeled as MEVB-F2 (second generation). Using the same method, the virus was passaged to passage 61, labeled as MEVB-F61.
[0023] (3) When the mink parvovirus MEVB was continuously passaged to the 10th generation (MEVB-F10), the virus was cloned and plaque-purified. The method is: dilute the virus to be purified 10 times to 10 -7 , take 10 -3 ~10 -7 0.1ml of v...
Embodiment 2
[0032] The preparation of embodiment 2 mink parvovirus enteritis live vaccine
[0033](1) Vaccine strain MEVB-F61 was inoculated on CRFK cells synchronously according to 0.1%-2% of the culture volume, and cultured in a 35°C spinner. Methods Harvest virus liquid. Five batches of vaccines were prepared according to the above method, and the virus content and purity were tested. The results showed that the virus titers (TCID) of the five batches of vaccines 50 )≥10 6.5 / ml, indicating that the vaccine strain MEVB-F61 has good production performance and is suitable for large-scale industrial production.
[0034] (2) Preparation of lyoprotectant
[0035] Dissolving gelatin, hydrolyzed milk protein and sucrose in water, according to the mass percentage, the final concentration of gelatin is 2-7%, the final concentration of hydrolyzed milk protein is 10-25%, and the final concentration of sucrose is 15-30%. Obtained after autoclaving at 116°C for 30 minutes.
[0036] (3) Mix th...
Embodiment 3
[0038] Example 3 Mink Parvovirus Enteritis Live Vaccine Safety Test
[0039] Get 3 batches of qualified mink parvovirus enteritis live vaccines (prepared by the method of embodiment 2), hindlimb muscle inoculation antibody negative mink, carry out single dose respectively (10 5.5 / head portion), single-dose repeated and over-dose (10 times) inoculation, while non-vaccinated mink was set as a control. After the vaccination, the body temperature, appetite, mental state and other physiological indicators of the minks were observed for 14 consecutive days, and the intestinal lesions of the vaccinated minks were observed by autopsy. The test results showed that after single-dose, repeated single-dose and over-dose vaccination, all the physiological indexes of the minks were normal, without any clinical symptoms, and there was no pathological change in the intestinal tract of the vaccinated mink. It shows that mink parvovirus enteritis live vaccine is safe for mink.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com